Literature DB >> 28717035

Neurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients.

Marie-Charlotte Quinton1, Sandra Bodeau1,2, Loay Kontar3, Yoann Zerbib3, Julien Maizel2,3, Michel Slama2,3, Kamel Masmoudi4, Anne-Sophie Lemaire-Hurtel1, Youssef Bennis5,2.   

Abstract

This retrospective cohort study included 53 patients admitted to the intensive care unit (ICU), with an average age of 69 years, without neurologic disorder before initiation of a continuous piperacillin infusion at the standard dose and who underwent piperacillin serum concentration monitoring. Among them, 23 developed a neurologic disorder for which the piperacillin causality was chronologically and semiologically suggestive. A concentration threshold of 157.2 mg/liter independently predicted neurotoxicity with 96.7% specificity and 52.2% sensitivity and may constitute a limitation when targeting less susceptible pathogens.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  intensive care unit; neurotoxicity; sepsis; therapeutic drug monitoring; β-lactams

Mesh：

Substances：

Year:  2017        PMID： 28717035      PMCID： PMC5571299          DOI： 10.1128/AAC.00654-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.

Authors:  Mohammad Reza Rafati; Mohammad Reza Rouini; Mojtaba Mojtahedzadeh; Atabak Najafi; Hassan Tavakoli; Kheirollah Gholami; Mohammad Reza Fazeli
Journal:  Int J Antimicrob Agents       Date:  2006-07-03       Impact factor: 5.283

2.  Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.

Authors:  Bernard Georges; Jean-Marie Conil; Stéphanie Ruiz; Thierry Seguin; Pierre Cougot; Olivier Fourcade; Georges Houin; Sylvie Saivin
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

Review 3.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

Review 4.  Prolonged infusion versus intermittent boluses of β-lactam antibiotics for treatment of acute infections: a meta-analysis.

Authors:  Jocelyn Teo; Yixin Liew; Winnie Lee; Andrea Lay-Hoon Kwa
Journal:  Int J Antimicrob Agents       Date:  2014-03-01       Impact factor: 5.283

5.  An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units.

Authors:  Gloria Wong; Alexander Brinkman; Russell J Benefield; Mieke Carlier; Jan J De Waele; Najoua El Helali; Otto Frey; Stephan Harbarth; Angela Huttner; Brett McWhinney; Benoit Misset; Federico Pea; Judit Preisenberger; Michael S Roberts; Thomas A Robertson; Anka Roehr; Fekade Bruck Sime; Fabio Silvio Taccone; Jacobus P J Ungerer; Jeffrey Lipman; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2014-01-16       Impact factor: 5.790

6.  Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs.

Authors:  Wieslawa Duszynska; Fabio Silvio Taccone; Marcin Switala; Magdalena Hurkacz; Beata Kowalska-Krochmal; Andrzej Kübler
Journal:  Int J Antimicrob Agents       Date:  2011-12-09       Impact factor: 5.283

Review 7.  Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside.

Authors:  K M Chow; A C Hui; C C Szeto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

8.  Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.

Authors:  Bernard Georges; Jean-Marie Conil; Thierry Seguin; Stéphanie Ruiz; Vincent Minville; Pierre Cougot; Jean-François Decun; Hélène Gonzalez; Georges Houin; Olivier Fourcade; Sylvie Saivin
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

Review 9.  Sepsis-associated encephalopathy.

Authors:  Teneille E Gofton; G Bryan Young
Journal:  Nat Rev Neurol       Date:  2012-09-18       Impact factor: 42.937

Review 10.  Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.

Authors:  Hui Yang; Chao Zhang; Quanyu Zhou; Yike Wang; Lujia Chen
Journal:  PLoS One       Date:  2015-01-09       Impact factor: 3.240
View more
  19 in total

Review 1.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy.

Authors:  J Petersson; C G Giske; E Eliasson
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection.

Authors:  Ashlan J Kunz Coyne; Mohammad Alshaer; Anthony M Casapao; Veena Venugopalan; Carmen Isache; Jason Ferreira; Christopher A Jankowski
Journal:  Antimicrob Agents Chemother       Date:  2022-09-08       Impact factor: 5.938

4.  Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools.

Authors:  Ferdinand Anton Weinelt; Miriam Songa Stegemann; Anja Theloe; Frieder Pfäfflin; Stephan Achterberg; Franz Weber; Lucas Dübel; Agata Mikolajewska; Alexander Uhrig; Peggy Kiessling; Wilhelm Huisinga; Robin Michelet; Stefanie Hennig; Charlotte Kloft
Journal:  Antibiotics (Basel)       Date:  2022-06-02

5.  Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients.

Authors:  Ibrahim El-Haffaf; Romain Guilhaumou; Lionel Velly; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2022-03-28       Impact factor: 5.577

6.  Evaluation of Prolonged Versus Continuous Infusions of Piperacillin/Tazobactam During Shortages of Small Volume Parenteral Solutions.

Authors:  Emily Tschumper; Kaitlyn Dupuis; Kim McCrory; Wes Pitts
Journal:  J Pharm Technol       Date:  2021-07-23

7.  Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Authors:  Kevin J Downes; Jennifer L Goldman
Journal:  Clin Pharmacol Ther       Date:  2021-02-27       Impact factor: 6.875

8.  Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment.

Authors:  Ute Chiriac; Otto R Frey; Anka C Roehr; Andreas Koeberer; Patrick Gronau; Thomas Fuchs; Jason A Roberts; Alexander Brinkmann
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

9.  Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?

Authors:  Helena Colom-Codina; Ariadna Padullés-Zamora; Erika Esteve-Pitarch; Víctor Daniel Gumucio-Sanguino; Sara Cobo-Sacristán; Evelyn Shaw; Kristel Maisterra-Santos; Joan Sabater-Riera; Xosé L Pérez-Fernandez; Raül Rigo-Bonnin; Fe Tubau-Quintano; Jordi Carratalà
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-06-15       Impact factor: 2.441

Review 10.  Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Authors:  Erin F Barreto; Andrew J Webb; Gwendolyn M Pais; Andrew D Rule; Paul J Jannetto; Marc H Scheetz
Journal:  Crit Care Explor       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.